WILMERHALE November 23, 2021 FOIA CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 28 C.F.R. § 16.8 AND 5 U.S.C. § 552 +1 212 230 8888 By E-mail And By FTP Assistant United States Attorney One St. Andrew's Plaza New York, New York 10007 Re: August II, 2019 Grand Jury Subpoenas to JPMorgan Chase Bank, N.A., Chase Bank USA, N.A., and J.P. Morgan Securities LLC; August 16, 2019 and September 3, 2019 Grand Jury Subpoenas to JP Morgan Chase; October 9, 2019 Grand Jury Subpoenas to JPMorgan Chase Bank N.A. And All Affiliates Dear In response to the above-referenced subpoenas and to your request by email on November 22, 2021, on behalf of our client JPMorgan Chase ("JPMorgan" or the "Finn"), we submit the enclosed encrypted zip file containing account documentation bates labeled JPM- SDNY-00065519 through JPM-SDNY-00065530. As discussed on November 22, 2021, this production includes account documentation related to account numb in the name of ASW Holdings, Inc. We also wanted to provide the following additional information about the documents in our November 22, 2021 production. The November 22, 2021 production included account documentation related to account numbei in the name of Financial Trust Company, Inc. (JPM-SDNY-00065487 through JPM-SDNY-00065493); account documentation related to account number in the name of Jeffrey Epstein (JPM-SDNY-00065494 throw h JPM-SDNY-00065499); and account documentation related to account number in the name of Ghislaine Maxwell (JPM-SDNY-00065500 through JPM-SDNY- 00065518). Should you require any additional materials, please do not hesitate to contact us. * * * Pursuant to the Freedom of Information Act ("FOIA"), 5 U.S.C. § 552, 28 C.F.R. § 16.8, and any other applicable law, rule, or regulation, Wilmer Cutler Pickering Hale and Don LLP requests on behalf of JPMorgan that confidential treatment be accorded to this letter (Bates numbered JPM-SDNY-CL-012-0001 through JPM-SDNY-CL-012-0003) and the referenced materials (Bates numbered JPM-SDNY-00065519 through JPM-SDNY-00065530 on JPM- Confidential Treatment Requested by JPMorgan Chase JPM-SDNY-CL-012-0001 EFTA00014878

WI LM ERHA LE November 23, 2021 Page 2 SDNY-VOL-012) (collectively, the "Confidential Material"). Accordingly, the Confidential Material has been marked "Confidential Treatment Requested by JPMorgan Chase." The Confidential Material contains confidential business information concerning JPMorgan. Furthermore, public disclosure of the Confidential Material could reasonably be expected to cause substantial competitive harm to JPMorgan. Accordingly, the Confidential Material is subject to, without limitation, Exemption 4 of the FOIA, 5 U.S.C. § 552(b)(4), and the Trade Secrets Act, 18 U.S.C. § 1905, and will continue to remain exempt from mandatory disclosure even after the conclusion of the Department of Justice's ("Department") consideration of this matter. We note further that, since the Confidential Material constitutes investigatory records obtained by the Department in connection with a potential law enforcement proceeding, such records are subject, at least at present, to the exemption from mandatory disclosure under Exemption 7(A) of the FOIA, 5 U.S.C. § 552(b)(7)(A).' Since the documents pertain to the activities of JPMorgan, its employees, and its clients and their employees and agents, and not to the activities of any federal agency, JPMorgan also believes the documents are exempt from disclosure pursuant to Exemption 7(C) of the FOIA, 5 U.S.C. § 552(b)(7)(C).2 Should any third person request the opportunity to inspect or copy the Confidential Material pursuant to the FOIA or otherwise, we request on behalf of JPMorgan that the undersigned immediately be notified of such request and be furnished with a copy of all written materials pertaining to such request (including but not limited to the request and any agency determination with respect to such request). JPMorgan expects that it will be given an opportunity to object to such disclosure. And, should the Department be inclined to grant any such request, it is JPMorgan's expectation that, pursuant to the procedures required by 28 C.F.R. § 16.8, and Exec. Order 12,600, 52 Fed. Reg. 23,781 (1987), we will be given reasonable advance notice of any such decision to enable our client to pursue any remedy that may be available to it.' In such event, we request that you telephone the undersigned rather than rely upon the United States mail for such notice. If the Department is not satisfied that the submission is exempt from disclosure pursuant to the FOIA, we stand ready to supply further particulars. The requests set forth in the preceding paragraphs also apply to any memoranda, notes, recordings, or other writings of any sort whatsoever which are made by, or at the request of, any employee of the Department (or any other government agency) and which (I) incorporate, include, or relate to any of the information contained in the Confidential Material; or (2) refer to any conference, meeting, telephone conversation, or interview between (a) our client's current or former employees, associates, representatives, agents, auditors, or counsel and (b) employees of the Department (or any other government agency). 2 3 See, e.g., NLRB v. Robbins Tire & Rubber Co., 437 U.S. 214 (1978). See Dept ofJustice v. Reports Comm. For Freedom of Press, 489 U.S. 749 (1989). See, e.g., Chrysler Corp. v. Brown, 441 U.S. 281 (1979). Confidential Treatment Requested by JPMorgan Chase JPM-SDNY-CL-012-0002 EFTA00014879

WI LM ERHA LE November 23, 2021 Page 3 This letter is not intended to, and does not, waive any applicable privilege or other legal basis under which information may not be subject to production. * * * If you have any questions, do not hesitate to contact me at the above-referenced number. Sincerely, Enclosure Confidential Treatment Requested by JPMorgan Chase JPM-SDNY-CL-012-0003 EFTA00014880